Dipna Pharmachem Share Price Today | Stock Price & Dipna Pharmachem Share Screener
Track the current Dipna Pharmachem share price and stock price live with TickJournal's free stock screener. Check DPL 52-week chart for the annual price range and momentum. Use the Dipna Pharmachem stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Dipna Pharmachem opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Over the trailing twelve months the company reported revenue of ₹129 and net income of ₹3, with EBITDA of ₹5, an operating margin of 4.0% and a profit margin of 2.3%.
Dipna Pharmachem Share Price Chart
Track the current stock price of Dipna Pharmachem with an interactive chart. Analyse DPL share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Dipna Pharmachem stock quote in one place.
Dipna Pharmachem Company Profile - Fundamental Screener
Screen Dipna Pharmachem company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for DPL shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare sector and the Pharmaceuticals industry, and it trades under ISIN INE0MC401013.
Company Details
Classification
Identifiers and Leadership
Dipna Pharmachem Balance Sheet Screener
Screen DPL balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2026, total assets were ₹206, up from ₹132 in 2025.
Latest statistics put total assets at ₹206 and shareholder funds at ₹62, with a leverage ratio of 0.48.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
Assets |
|||||||||
| Total Assets | 206 | 132 | 133 | 78 | 36 | 25 | 18 | 14 | 11 |
| Current Assets | 154 | 132 | 133 | 78 | 36 | 25 | 18 | 14 | 11 |
| Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Liabilities |
|||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 10 | 9 | 13 | 11 | 6 | 4 | 0 | 0 | 0 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Shareholders' Equity |
|||||||||
| Total Equity | 62 | 39 | 38 | 24 | 2 | 1 | 1 | 1 | 1 |
| Share Capital | 26 | 24 | 24 | 12 | 0 | 0 | 0 | 0 | 0 |
| Reserves & Surplus | 36 | 14 | 14 | 12 | 2 | 1 | 1 | 1 | 0 |
Dipna Pharmachem Income Statement Screener - Profit & Revenue Analysis
Screen Dipna Pharmachem income statement and profit fundamentals. Analyze DPL quarterly results. Dipna Pharmachem reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For 2026-March, revenue was ₹129 and net profit was ₹3, equal to earnings per unit of ₹1.00, at an operating margin of 4%.
In that period expenses were ₹124, interest cost ₹1 and tax ₹1. The next period listed, 2025-March, shows revenue of ₹125 and net profit of ₹1.
| Item | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March |
|---|---|---|---|---|---|---|---|---|---|
Revenue and Expenses | |||||||||
| Revenue | 129 | 125 | 164 | 100 | 73 | 31 | 31 | 20 | 17 |
| Expenses | 124 | 122 | 161 | 98 | 71 | 31 | 31 | 20 | 17 |
Operating Costs and Margins | |||||||||
| EBITDA | 5 | 3 | 3 | 2 | 2 | 0 | 0 | 0 | 0 |
| Operating Profit % | 4.00% | 3.00% | 2.00% | 2.00% | 3.00% | 1.00% | 0.00% | 0.00% | 0.00% |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 1 | 2 | 2 | 1 | 1 | 0 | 0 | 0 | 0 |
Profit and Earnings | |||||||||
| Profit Before Tax | 4 | 1 | 1 | 1 | 2 | 0 | 0 | 0 | 0 |
| Tax | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Net Profit | 3 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| EPS | 1.00 | 0.41 | 0.45 | 0.76 | 333.39 | 6.91 | 16.86 | 9.15 | 17.27 |
Dipna Pharmachem Cash Flow Screener - Liquidity Fundamentals
Screen DPL cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2025-March, operating activities used ₹9, and net cash flow was an outflow of ₹13.
Over the same period, investing activities provided ₹0 and financing activities used ₹4.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March |
|---|---|---|---|---|---|---|
Cash from Operations and Investing | ||||||
| Operating Activities | -9 | -5 | -21 | 3 | -2 | -3 |
| Investing Activities | 0 | 0 | 0 | 0 | 0 | 0 |
Financing and Net Cash | ||||||
| Financing Activities | -4 | 14 | 27 | -3 | 3 | 3 |
| Net Cash Flow | -13 | 8 | 6 | 0 | 0 | 0 |
Dipna Pharmachem Shareholding Pattern Screener
See Dipna Pharmachem shareholding pattern with promoter, FII, and DII holdings. Check Dipna Pharmachem promoter holding and ownership changes for DPL on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Mar, promoters held 9.13%, foreign institutions 0.00%, domestic institutions 0.00% and the public 79.16%, spread across 1,717 shareholders.
The shareholder count was 1,717 in 2026-Mar, compared with 1,788 in 2026-Jun.
| Item | 2026-Mar | 2026-Jun | 2025-Mar | 2025-Sept | 2025-Nov | 2024-Mar | 2024-Sept | 2023-Mar |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 9.13% | 9.13% | 9.98% | 9.98% | 9.13% | 9.98% | 9.98% | 66.56% |
Institutional Investors | ||||||||
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Government, Public and Others | ||||||||
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 79.16% | 81.17% | 71.21% | 73.74% | 79.11% | 63.07% | 81.82% | 31.36% |
| Other Holding | 11.71% | 9.71% | 18.81% | 16.28% | 11.76% | 26.95% | 8.20% | 2.08% |
| Shareholder Count | 1,717 | 1,788 | 1,997 | 1,742 | 1,741 | 1,807 | 2,652 | 992 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Dipna Pharmachem. Dipna Pharmachem dividend yield can be compared with peers and other stocks in the market.
Dipna Pharmachem Stock Index Membership - Nifty & Sensex
See which indices include Dipna Pharmachem stock. Check DPL index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
Complete Index List
Dipna Pharmachem Market Events Screener - Corporate Actions
Get Dipna Pharmachem corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Dipna Pharmachem stock events that may affect DPL share price, along with derivatives, futures and options activity and sector gainers.
9 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated July 2, 2026, with a record date of July 2, 2026.
It is followed by Quarterly Result Announcement dated November 26, 2025 and Annual General Meeting dated August 30, 2025.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-07-02 | 2026-07-02 | Quarterly Result Announcement | NA | -9.72% |
| 2025-11-26 | 2025-11-26 | Quarterly Result Announcement | NA | -10.55% |
| 2025-08-30 | 2025-08-30 | Annual General Meeting | NA | -5.94% |
| 2025-07-07 | 2025-07-07 | Quarterly Result Announcement | NA | 3.65% |
| 2025-04-04 | 2025-04-04 | Extraordinary General Meeting | NA | 10.31% |
| 2024-12-11 | 2024-12-11 | Quarterly Result Announcement | NA | 0.00% |
| 2024-08-27 | 2024-08-27 | Annual General Meeting | NA | 15.01% |
| 2024-02-12 | 2024-02-12 | Rights | 13:12 | 27.52% |
| 2024-01-03 | 2024-01-03 | Extraordinary General Meeting | NA | -10.98% |
Dipna Pharmachem Competitors Screener - Peer Stocks Comparison
Screen DPL competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 447,476 | 36.44 | 61,674 | 12.69% | 11,565 | 47.42 |
| Divis Laboratories | 250,363 | 86.51 | 11,067 | 13.95% | 2,568 | 58.71 |
| Torrent Pharmaceuticals | 186,152 | 85.91 | 13,886 | 20.34% | 2,138 | 48.14 |
| Zydus Life Science | 120,798 | 26.32 | 27,658 | 17.64% | 5,026 | 61.81 |
| Cipla | 111,426 | 33.44 | 29,045 | 2.24% | 3,870 | 44.03 |
| Laurus Labs | 106,838 | 99.70 | 6,868 | 22.01% | 890 | 58.00 |
| Mankind Pharma | 105,107 | 48.73 | 14,636 | 14.85% | 1,938 | 64.24 |
| Dr Reddys Laboratories | 104,492 | 32.05 | 35,059 | 3.90% | 4,158 | 69.59 |
| Aurobindo Pharma | 97,682 | 26.36 | 34,145 | 5.56% | 3,503 | 54.69 |
| Lupin | 93,829 | 16.99 | 29,039 | 26.75% | 5,356 | 34.02 |
Dipna Pharmachem Company Announcements - News & Reports Screener
Screen DPL latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated July 15, 2026.
The next most recent announcements are dated July 6, 2026 and July 2, 2026.
| Date | Update | Actions |
|---|---|---|
| 2026-07-15 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-07-06 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-07-02 | Submission Of Integrated Financials | - |
| 2026-07-02 | Submission Of Statement Of Deviation And Variation | - |
| 2026-07-02 | Submission Of Financial Results | - |
| 2026-07-02 | Board Meeting Outcome for Outcome Of Board Meeting Held Today I.E. 2Nd July 2026 | - |
| 2026-07-02 | Announcement under Regulation 30 (LODR)-Resignation of Director | - |
| 2026-07-02 | Announcement under Regulation 30 (LODR)-Resignation of Director | - |
| 2026-07-02 | Announcement under Regulation 30 (LODR)-Change in Directorate | - |
| 2026-07-02 | Board Meeting Outcome for Outcome And Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 | - |
| 2026-07-01 | Board Meeting Outcome for Outcome And Intimation For Rescheduling Of Board Meeting To 2Nd July 2026 | - |
| 2026-07-01 | Board Meeting Intimation for Outcome And Intimation For Rescheduling Of Board Meeting To 2Nd July 2026 | - |
| 2026-06-30 | Closure of Trading Window | - |
| 2026-06-27 | Board Meeting Intimation for Intimation Of Board Meeting To Be Held On Wednesday 1St July 2026 | - |
| 2026-05-30 | Compliances-Reg.24(A)-Annual Secretarial Compliance | - |
| 2026-05-25 | Voting Results For Postal Ballot | - |
| 2026-05-25 | Shareholder Meeting / Postal Ballot-Scrutinizer"s Report | - |
| 2026-04-24 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-04-22 | Shareholder Meeting / Postal Ballot-Notice of Postal Ballot | - |
| 2026-04-22 | Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 | - |
Frequently Asked Questions
How is the company valued right now?
The P/E ratio is 4.57 and the P/B ratio is 0.19, with earnings per unit of ₹1.00. Market capitalisation stands at ₹11.87 Cr. The company operates in the Healthcare sector, in the Pharmaceuticals industry, so compare these ratios with its sector peers in the table above.
About This Data
Key statistics were last updated on October 5, 2026. This page covers 9 balance sheet periods, 9 income statement periods, 6 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.